Who is eligible for clinical trial NCT06109779?

Participants must meet protocol criteria for Biliary Tract Cancer. Confirm exact inclusion and exclusion requirements with the study coordinator.

Does clinical trial NCT06109779 provide travel or cost reimbursement?

Check with the site coordinator at the participating facility for travel and lodging stipend availability, and for which routine-care costs are covered.

🏛️ Verified NIH Record • Updated 2026-07-09

Rilvegostomig + Chemotherapy as Adjuvant Therapy for Biliary Tract Cancer After Resection (ARTEMIDE-Biliary01) (NCT06109779)

A Phase III, Randomized, Double-Blind, Placebo-Controlled, Multicenter, Global Study of Rilvegostomig in Combination With Chemotherapy as Adjuvant Treatment After Resection of Biliary Tract Cancer With Curative Intent (ARTEMIDE-Biliary01)

🔵 Active, Not Recruiting Phase3 💊 Investigational Drug / Biologic Sponsor: AstraZeneca

🩺 Plain-English Summary (8th-Grade Level)

A global study to assess the efficacy and tolerability of rilvegostomig compared to placebo in combination with investigator's choice of chemotherapy in participants with BTC after surgical resection with curative intent.

Who can join: Review the eligibility criteria below.

Location: Research Site — Birmingham, Alabama

Age range: 18 Years

🧪 Interventions in This Study

📋 "Do I Qualify?" — 1-Minute Self Screener

Instant Checklist

Full eligibility criteria are available on the official NIH protocol. View the criteria ↗

📍 All Participating Trial Locations (177 Sites)

Showing the first 25 of 177 sites.

Research Site — Birmingham, Alabama
Research Site — Phoenix, Arizona
Research Site — Los Angeles, California
Research Site — Orange, California
Research Site — Stanford, California
Research Site — Aurora, Colorado
Research Site — Littleton, Colorado
Research Site — Washington D.C., District of Columbia
Research Site — Jacksonville, Florida
Research Site — Atlanta, Georgia
Research Site — Chicago, Illinois
Research Site — Iowa City, Iowa
Research Site — Kansas City, Kansas
Research Site — Lexington, Kentucky
Research Site — New Orleans, Louisiana
Research Site — Grand Rapids, Michigan
Research Site — Rochester, Minnesota
Research Site — St Louis, Missouri
Research Site — Commack, New York
Research Site — Mineola, New York
Research Site — Philadelphia, Pennsylvania
Research Site — Dallas, Texas
Research Site — Camperdown,
Research Site — Clayton,
Research Site — Murdoch,

💰 Cost, Insurance & Patient Rights

100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
Voluntary Participation: You may withdraw at any time without affecting your standard medical care.

More studies in Biliary Tract Cancer

Adoptive Transfer of Tumor Infiltrating Lymphocytes for Biliary Tract Cancers — Pittsburgh, Pennsylvania
A Study of Ramucirumab (LY3009806) or Merestinib (LY2801653) in Advanced or Metastatic Biliary Tract Cancer — Tucson, Arizona
Durvalumab With Chemotherapy as First Line Treatment in Patients With Advanced Biliary Tract Cancers (aBTCs) — Mobile, Alabama
XmAb20717 in Advanced Biliary Tract Cancers — Philadelphia, Pennsylvania
A Study of CTX-009 in Combination With Paclitaxel in Adult Patients With Unresectable Advanced, Metastatic or Recurrent Biliary Tract Cancers (COMPANION-002) — Phoenix, Arizona

Explore by condition: All Biliary Tract Cancer clinical trials

💡 How to Participate

Check the checklist above to see if you may qualify.
Review the official NIH record below to find the coordinating site.
Ask about the visit schedule, what is covered at no cost, and any travel support.
Confirm with your own doctor before making a decision.

🏛️ View Official NIH Record ↗